American Journal of Epidemiology Advance Access published online on July 17, 2006
American Journal of Epidemiology, doi:10.1093/aje/kwj250
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 University of California, San Diego, CA
* To whom correspondence should be addressed. The purpose of this study was to test the hypothesis that aspirin use is associated with a decreased risk of incident colorectal cancer. From the Women's Health Initiative, 91,574 participants between the ages of 50 and 79 years at baseline in 1993-1998 provided details on aspirin use via interview using a standardized questionnaire and were subsequently followed annually for incident colorectal cancer during a period of over 6 years. For those persons who reported aspirin use, the type of compound, dose, and duration of use were recorded. Medical histories suggestive of colorectal cancers at the annual update were verified by medical record and pathology report review by trained local physician adjudicators. There were 631 confirmed cases of invasive cancer of the colon or rectum. There was no significant association between any aspirin use and risk for incident colorectal cancer (hazard ratio = 0.96, 95% confidence interval: 0.8, 1.2). Moreover, with no aspirin use as the referent category, there were no significant associations for duration of aspirin intake by category (<1, 1-<2, 2-<3, 3-<4, 4-<5, and
Received December 9, 2005
Accepted March 20, 2006
ORIGINAL CONTRIBUTIONS
The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women
Matthew Allison 1 *, Cedric Garland 1, Rowan Chlebowski 2, Michael Criqui 1, Robert Langer 3, Lieling Wu 4, Hemant Roy 5, Anne McTiernan 4, and Lewis Kuller 6, for the Women's Health Initiative Investigators
2 Los Angeles Biomedical Research Institute, Torrance, CA
3 Geisinger Health Systems, Danville, PA
4 Fred Hutchinson Cancer Research Center, Seattle, WA
5 Northwestern University, Chicago, IL
6 University of Pittsburgh, Pittsburgh, PA
Matthew Allison, E-mail: mallison{at}ucsd.edu
![]()
Abstract
5 years) or for daily dosage by category (<165, 165-<300, 300-<495, or
495 mg).![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Bardia, J. O. Ebbert, R. A. Vierkant, P. J. Limburg, K. Anderson, A. H. Wang, J. E. Olson, C. M. Vachon, and J. R. Cerhan Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality J Natl Cancer Inst, June 6, 2007; 99(11): 881 - 889. [Abstract] [Full Text] [PDF] |
||||
